ClinicalTrials.gg
CompletedNCT05119686Updated May 12, 2023

Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients

A Phase 2 interventional study of AR882 Dose 1 and AR882 Dose 2 in Gout, Arthritis, Gouty and Hyperuricemia, sponsored by Arthrosi Therapeutics. Completed at 23 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-05-12.

Primary conditionArthritis, GoutyRegistry: GoutReclassifiedWhy we changed it
Registry
Gout — the first condition term the registry derived for this study.
ClinicalTrials.gg
Arthritis, Gouty
Why
  1. The study's listed conditions name Arthritis, Gouty, a narrower term within Gout.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Arthrosi Therapeutics (part of Swedish Orphan Biovitrum) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2022, 3 years 11 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in May 2023.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies in Arthritis, Gouty with a site in United States — 3 open to participants now, 4 under way, 1 of them phase 3. Arthritis, Gouty · United States.

Enrollment
9th of 14
140 · median 225
Started
2021
the only one that year
Phase 2
6 of 15
none open now
Registered
8th of 15
by date
Lead sponsor
5 of 15
Arthrosi Therapeutics

Among the 15 studies in Arthritis, Gouty with a site in United States, this one is the 9th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2021, is one of 6 in phase 2, and was the 8th registered.

Arthritis, Gouty

47 studies on the registry are indexed under Arthritis, Gouty; 16 are open to participants now.

Browse Arthritis, Gouty studies →

Open to participants now

3 of the 15 studies in Arthritis, Gouty with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 10 Arthritis, Gouty studies recruiting now, 8 (80%) set no upper age limit and 1 (10%) stops at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Arthritis, Gouty with a site in United States, or all of them as a file.
02

Study summary

This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 weeks.

03

Conditions studied

  • Gout
  • Arthritis, Gouty
  • Hyperuricemia
  • Gout Chronic

Browse trials for

04

In context

Arthritis, Gouty Reclassified

47 studies on the registry are indexed under Arthritis, Gouty; 16 are open to participants now.

This study's enrollment of 140 is close to the median of 140 across 35 interventional studies indexed under Arthritis, Gouty.

Browse Arthritis, Gouty studies →

Lead sponsor

Arthrosi Therapeutics is the lead sponsor of 10 studies on the registry; none are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

First submitted before Arthrosi Therapeutics became part of Swedish Orphan Biovitrum.

Compared within Arthritis, Gouty, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Gout. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of gout
  • sUA > 7 mg/dL
  • Estimated (eGFR) ≥ 30 mL/min/1.73m2

Exclusion criteria

Exclusion Criteria:

  • within 5 years, except for successfully treated basal or squamous cell carcinoma of the skin
  • History of cardiac abnormalities
  • History of kidney stones
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
140 participants (actual)

Study arms

  • Experimental
    Group 1

    AR882 Dose 1 x 12 weeks

    Drug: AR882 Dose 1

  • Experimental
    Group 2

    AR882 Dose 1 x 2 weeks, then Dose 2 x 10 weeks

    Drug: AR882 Dose 1 · Drug: AR882 Dose 2

  • Placebo comparator
    Group 3

    AR882 matching placebo x 12 weeks

    Drug: Placebo

Interventions

07

What researchers measure

Primary outcomes

  1. Serum urate (uric acid) (sUA) level < 6 mg/dL following 6 weeks of dosing

    Comparison of the treatment groups for the proportion of patients with serum urate (uric acid) (sUA) level \< 6 mg/dL following 6 weeks of dosing

    Time frame: 6 weeks

Secondary outcomes

  1. sUA levels < 5, < 4, and < 3 mg/dL

    Comparison of the treatment groups for proportion of patients whose sUA levels are \< 5, \< 4, and \< 3 mg/dL

    Time frame: 6 weeks

  2. Incidence of Adverse Events

    Treatment Emergent Adverse Events and Serious Adverse Event incidence.

    Time frame: 14 weeks

  3. Maximum Observed Plasma Concentration (Cmax)

    Plasma samples will be collected to assess plasma concentrations at a series of timepoints to derive Cmax.

    Time frame: 12 weeks

  4. Time to observed Cmax (Tmax)

    Plasma samples will be collected to assess plasma concentrations at a series of timepoints to derive Tmax.

    Time frame: 12 weeks

  5. Area under the plasma concentration-time curve (AUC)

    Plasma samples will be collected to assess plasma concentrations at a series of timepoints to derive AUC.

    Time frame: 12 weeks

08

Study locations

23 sites
  • Arthrosi Investigative Site
    Gilbert, Arizona 85297, United States
  • Arthrosi Investigative Site
    Sun City, Arizona 85351, United States
  • Arthrosi Investigative Site
    Tucson, Arizona 85704, United States
  • Arthrosi Investigative Site
    Miami Lakes, Florida 33014, United States
  • Arthrosi Investigative Site
    Miami, Florida 33143, United States
  • Arthrosi Investigative Site
    Tampa, Florida 33613, United States
  • Arthrosi Investigative Site
    Honolulu, Hawaii 96814, United States
  • Arthrosi Investigative Site
    Overland Park, Kansas 66212, United States
  • Arthrosi Investigative Site
    Cleveland, Ohio 44122, United States
  • Arthrosi Investigative Site
    Cleveland, Ohio 44195, United States
  • Arthrosi Investigative Site
    Duncansville, Pennsylvania 16635, United States
  • Arthrosi Investigative Site
    Dallas, Texas 75231, United States
  • Arthrosi Investigative Site
    Houston, Texas 77074, United States
  • Arthrosi Investigative Site
    Tomball, Texas 77375, United States
  • Arthrosi Investigative Site
    West Jordan, Utah 84088, United States
  • Arthrosi Investigative Site
    Glendale, Wisconsin 53217, United States
  • Arthrosi Investigative Site
    Melbourne, Camberwell 3124, Australia
  • Arthrosi investigative Site
    Botany, New South Wales 2019, Australia
  • Arthrosi Investigative Site
    Taichung City, 402, Taiwan
  • Arthrosi Investigative Site - 301
    Taipei City, 112, Taiwan
  • Arthrosi Investigative Site - 304
    Taipei City, 112, Taiwan
  • Arthrosi Investigative Site
    Taipei City, 114, Taiwan
  • Arthrosi Investigative Site
    Taoyuan, 333, Taiwan
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Nov 2022, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2021
First posted
Nov 15, 2021
StartActual
Nov 16, 2021
Primary completionActual
Nov 17, 2022
CompletionActual
Nov 17, 2022
Results delay requested
May 6, 2023
Last update
May 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05119686
Responsible party
Sponsor
First posted
Nov 15, 2021
Start date
Nov 16, 2021
Primary completion
Nov 17, 2022
Completion
Nov 17, 2022
Last update
May 12, 2023

Study contacts

R Keenan, MD
study chair · Arthrosi Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AR882

Start the discussion